Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Several other analysts also recently issued reports on APTO. Canaccord Genuity Group lowered their price target on Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a report on Thursday, May 16th. Piper Sandler reiterated an overweight rating and issued a $5.00 price target on shares of Aptose Biosciences in a report on Wednesday, April 3rd. Finally, HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Aptose Biosciences in a report on Friday, June 14th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Aptose Biosciences has a consensus rating of Moderate Buy and a consensus price target of $14.83.

Aptose Biosciences Stock Down 6.5 %

APTO stock opened at $0.49 on Thursday. The company has a market cap of $8.86 million, a price-to-earnings ratio of -0.08 and a beta of 1.27. The business has a fifty day simple moving average of $0.78 and a 200-day simple moving average of $1.30. Aptose Biosciences has a 52 week low of $0.47 and a 52 week high of $5.10.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.09. As a group, analysts expect that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned about 0.16% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.